Source-grounded facts extracted from BridgeBio Oncology Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Michelle Doig resigned as Class I director at BridgeBio Oncology Therapeutics, Inc..
“On June 16, 2026, Michelle Doig notified BridgeBio Oncology Therapeutics, Inc. (the “Company”), of her resignation as a member of the Board of Directors of the Company (the “Board”) upon the completion of her term as a Class I director, effective as of June 16, 2026, the date of the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”
BridgeBio Oncology Therapeutics, Inc. shareholders approved Ratification of Appointment of Independent Registered Accounting Firm at the 2026-06-16 meeting.
“Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm. The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions 34,535,875 3,440 0 There were zero broker non-votes and 13,805,126 no votes regarding this proposal.”
BridgeBio Oncology Therapeutics, Inc. shareholders approved Election of Directors at the 2026-06-16 meeting.
“Proposal 1 - Election of Directors. The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class I directors to hold office until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. Director Nominee Votes For Votes Withheld Peter Lebowitz, M.D., Ph.D. 31,822,504 3,372 Frank P. McCormick, Ph.D., F.R.S., D. Sc. 25,654,119 6,171,757 There were 2,713,439 broker non-votes and 13,805,126 no votes regarding this proposal.”
BridgeBio Oncology Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $42.1 million for the first quarter of 2026 compared to $22.1 million for the first qu.
“BridgeBio Oncology Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Pedro J. Beltran was appointed as Member of the Board of Directors at BridgeBio Oncology Therapeutics, Inc..
“Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.”
Pedro J. Beltran was appointed as President and Chief Executive Officer at BridgeBio Oncology Therapeutics, Inc..
“Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.”
Eli Wallace resigned as Member of the Board of Directors at BridgeBio Oncology Therapeutics, Inc..
“Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.”
Eli Wallace resigned as President and Chief Executive Officer at BridgeBio Oncology Therapeutics, Inc..
“Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.”
BridgeBio Oncology Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
“BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update”
BridgeBio Oncology Therapeutics, Inc.: Helix ceased to be a shell company upon closing of the Business Combination.
“Upon the closing of the Business Combination, Helix ceased to be a shell company.”
BridgeBio Oncology Therapeutics, Inc.: Approved and adopted a new Code of Ethics in connection with closing of the Business Combination.
“In connection with the closing of the Business Combination, the PubCo Board approved and adopted a new Code of Ethics is applicable to all of PubCo’s employees, officers (including its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions), agents and representatives, including directors and consultants, and will be available on PubCo’s website at https://www.bbotx.com.”
BridgeBio Oncology Therapeutics, Inc.: Approved and adopted PubCo Bylaws effective as of the Effective Time on August 11, 2025 (effective 2025-08-11).
“On August 11, 2025, the PubCo Board approved and adopted the PubCo Bylaws containing the amendments proposed by the Organizational Documents Proposal and Advisory Organizational Documents Proposal and approved at the EGM, which became effective as of the Effective Time.”
BridgeBio Oncology Therapeutics, Inc.: Adopted PubCo Charter effective upon filing with Delaware Secretary of State on August 11, 2025 (effective 2025-08-11).
“The PubCo Charter, which became effective upon filing with the Secretary of State of the State of Delaware on August 11, 2025, includes the amendments proposed by the Domestication Proposal, the Organizational Documents Proposal and the Advisory Organizational Documents Proposals and approved at the EGM.”
BridgeBio Oncology Therapeutics, Inc. completed an acquisition involving TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) (closed 2025-08-11).
“On August 11, 2025 (the “Closing Date”), Helix Acquisition Corp. II., a Cayman Islands exempted company (“Helix”), consummated the previously announced business combination pursuant to the terms of the business combination agreement, dated February 28, 2025 and amended on June 17, 2025 (as amended, the “Business Combination Agreement”), with Helix II Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DYNS (“Merger Sub”), and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics), a Delaware corporation (“BBOT”).”
BridgeBio Oncology Therapeutics, Inc.: Amended and restated memorandum and articles of association filed and became effective in connection with IPO (effective 2024-02-08).
“On February 8, 2024, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “ Amended Charter ”) with the Cayman Islands General Registry, effective the same day.”
BridgeBio Oncology Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC (effective 2024-02-08).
“n January 18, 2024 (as amended, the “ Registration Statement ”): ● An Underwriting Agreement, dated February 8, 2024, between the Company and Leerink Partners LLC, a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference.”
John Schmid was appointed as Director at BridgeBio Oncology Therapeutics, Inc..
“Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company”
Mark C. McKenna was appointed as Director at BridgeBio Oncology Therapeutics, Inc..
“Mr. Mark C. McKenna and Mr. John Schmid (the “ Directors ”) were appointed to the board of directors of the Company”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.